Development of Bispecific Antibody Derivatives for Cancer ImmunotherapyHe, Y., Helfrich, W. & Bremer, E., 2019, Cancer Immunosurveillance: Methods and Protocols. Humana Press, p. 335-347 13 p. (Methods in Molecular Biology).
Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review
Development of antibody-based immunotherapeutics has progressed from direct tumor-targeting, with antibodies such as rituximab, to blocking of immune checkpoints to reactivate antitumor immunity. In addition, bispecific antibodies/antibody fragments are also of great interest in cancer therapy, as these constructs have the ability to redirect immune effector cells to cancer targets and, thereby, enhance therapeutic efficacy. A number of bispecific antibody formats have been reported, with the first FDA-approved bispecific antibody being blinatumomab, a so-called bispecific T cell engager (BiTE), which redirects and potently activates T cell immune responses. Recently, we described an additional novel bispecific antibody derivative, termed RTX-CD47, which was designed to inhibit the innate immune checkpoint CD47-SIRPα only on -positive cancer cells. RTX-CD47 contains two antibody fragments in tandem and has monovalent binding specificity for CD47 and . Only upon dual binding to and CD47 RTX-CD47 blocks CD47 "Don't eat me" signaling. Here, we provide a detailed protocol for the construction and functional evaluation of such a bispecific antibody derivative.
|Title of host publication||Cancer Immunosurveillance|
|Subtitle of host publication||Methods and Protocols|
|Number of pages||13|
|Publication status||Published - 2019|
|Name||Methods in Molecular Biology|